arrow_back Back to App

Faster Access to Affordable Medicines: Ending Approval Delays

This act aims to speed up the market entry of more affordable generic medicines. The changes will make it harder for pharmaceutical companies to block new drug approvals by filing unjustified petitions. This means citizens could gain quicker access to more affordable treatments.
Key points
Officials can deny petitions primarily intended to delay drug approvals, speeding up access to medicines.
Clear criteria are introduced to identify delaying petitions, such as late submission or repeated issues.
Companies filing delaying petitions will be reported to the Federal Trade Commission, potentially leading to further action.
Petitions must be submitted within 60 days of obtaining the information they are based on, preventing intentional delays.
Reporting to Congress will be required on petitions, their processing time, and their impact on drug approval delays.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_2843
Sponsor: Rep. Levin, Andy [D-MI-9]
Process start date: 2021-04-26
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

STOP GAMES Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_2843.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-26.

What are the main provisions?

Key points include:

  • Officials can deny petitions primarily intended to delay drug approvals, speeding up access to medicines.
  • Clear criteria are introduced to identify delaying petitions, such as late submission or repeated issues.
  • Companies filing delaying petitions will be reported to the Federal Trade Commission, potentially leading to further action.
  • Petitions must be submitted within 60 days of obtaining the information they are based on, preventing intentional delays.
  • Reporting to Congress will be required on petitions, their processing time, and their impact on drug approval delays.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Levin, Andy [D-MI-9].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Courts and Law Economy